Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Piperacillin/tazobactam vs carbapenems for patients with bacterial infection: Protocol for a systematic review.

Petersen MW, Perner A, Sjövall F, Jonsson AB, Steensen M, Andersen JS, Achiam MP, Frimodt-Møller N, Møller MH.

Acta Anaesthesiol Scand. 2019 Aug;63(7):973-978. doi: 10.1111/aas.13382. Epub 2019 Apr 24. Review.

PMID:
31020663
2.

Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.

Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, Rogers BA, McBryde ES, Roberts JA, Lipman J, Athan E, Paul SK, Baker P, Harris-Brown T, Paterson DL.

Trials. 2015 Jan 27;16:24. doi: 10.1186/s13063-014-0541-9.

3.

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.

Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj S, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke D, Miyakis S, Walls G, Al Khamis M, Zikri A, Crowe A, Ingram P, Daneman N, Griffin P, Athan E, Lorenc P, Baker P, Roberts L, Beatson SA, Peleg AY, Harris-Brown T, Paterson DL; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN).

JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163. Erratum in: JAMA. 2019 Jun 18;321(23):2370.

4.

Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.

Ng TM, Khong WX, Harris PN, De PP, Chow A, Tambyah PA, Lye DC.

PLoS One. 2016 Apr 22;11(4):e0153696. doi: 10.1371/journal.pone.0153696. eCollection 2016.

5.

Empirical metronidazole for patients with severe bacterial infection: protocol for a systematic review.

Petersen MW, Perner A, Bahador M, Sjövall F, Møller MH.

Acta Anaesthesiol Scand. 2018 May;62(5):724-730. doi: 10.1111/aas.13101. Epub 2018 Mar 8.

PMID:
29520759
6.

Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE; Antibacterial Resistance Leadership Group.

Clin Infect Dis. 2015 May 1;60(9):1319-25. doi: 10.1093/cid/civ003. Epub 2015 Jan 13. Erratum in: Clin Infect Dis. 2015 Jul 1;61(1):143.

7.

Ceftazidime, carbapenems, or piperacillin-tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection - a multi-site retrospective study.

Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Abdel Fattah M, Haquin J, Macgowan A, Grier S, Gibbs J, Chazan B, Yanovskay A, Ben Ami R, Landes M, Nesher L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, Buhl M, Mauer S, Bano JR, Morales I, Oliver A, Ruiz de Gopegui E, Cano A, Machuca I, Gozalo-Marguello M, Martinez LM, Gonzalez-Barbera EM, Alfaro IG, Salavert M, Beovic B, Saje A, Mueller-Premru M, Pagani L, Vitrat V, Kofteridis D, Zacharioudaki M, Maraki S, Weissman Y, Paul M, Dickstein Y, Leibovici L, Yahav D.

Clin Infect Dis. 2019 Jul 17. pii: ciz668. doi: 10.1093/cid/ciz668. [Epub ahead of print]

PMID:
31323088
8.

[Piperacillin/tazobactam--Tazocin. A penicillin-based alternative to 3rd generation cephalosporins and carbapenems].

Schønning K, Tvede M.

Ugeskr Laeger. 2002 May 13;164(20):2606-10. Review. Danish.

PMID:
12043402
9.

Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.

Paul M, Yahav D, Bivas A, Fraser A, Leibovici L.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD005197. doi: 10.1002/14651858.CD005197.pub3. Review.

PMID:
21069685
10.

Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.

Oztoprak N, Piskin N, Aydemir H, Celebi G, Akduman D, Keskin AS, Gokmen A, Engin H, Ankarali H.

Jpn J Clin Oncol. 2010 Aug;40(8):761-7. doi: 10.1093/jjco/hyq046. Epub 2010 Apr 28.

PMID:
20427546
11.

Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.

Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ.

Clin Infect Dis. 2013 Jan;56(2):272-82. doi: 10.1093/cid/cis857. Epub 2012 Oct 16. Review.

PMID:
23074314
12.

Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.

Khoo AL, Zhao YJ, Teng M, Ying D, Jin J, Chee YL, Poon LM, Lim SE, Koh LP, Chng WJ, Lim BP, Hsu LY, Chai LYA.

Int J Antimicrob Agents. 2018 Sep;52(3):350-357. doi: 10.1016/j.ijantimicag.2018.04.017. Epub 2018 May 9.

PMID:
29751120
13.

Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.

Young M, Plosker GL.

Pharmacoeconomics. 2001;19(11):1135-75. Review.

PMID:
11735679
14.

Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.

Tsai HY, Chen YH, Tang HJ, Huang CC, Liao CH, Chu FY, Chuang YC, Sheng WH, Ko WC, Hsueh PR.

Diagn Microbiol Infect Dis. 2014 Nov;80(3):222-6. doi: 10.1016/j.diagmicrobio.2014.07.006. Epub 2014 Jul 26.

PMID:
25139843
15.

Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.

Docobo-Pérez F, López-Cerero L, López-Rojas R, Egea P, Domínguez-Herrera J, Rodríguez-Baño J, Pascual A, Pachón J.

Antimicrob Agents Chemother. 2013 May;57(5):2109-13. doi: 10.1128/AAC.02190-12. Epub 2013 Feb 25.

16.

Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.

Ko JH, Lee NR, Joo EJ, Moon SY, Choi JK, Park DA, Peck KR.

Eur J Clin Microbiol Infect Dis. 2018 Feb;37(2):305-311. doi: 10.1007/s10096-017-3133-2. Epub 2017 Nov 25.

PMID:
29177611
17.

Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.

Ofer-Friedman H, Shefler C, Sharma S, Tirosh A, Tal-Jasper R, Kandipalli D, Sharma S, Bathina P, Kaplansky T, Maskit M, Azouri T, Lazarovitch T, Zaidenstein R, Kaye KS, Marchaim D.

Infect Control Hosp Epidemiol. 2015 Aug;36(8):981-5. doi: 10.1017/ice.2015.101. Epub 2015 May 20.

PMID:
25990361
19.
20.

Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.

Paul M, Yahav D, Fraser A, Leibovici L.

J Antimicrob Chemother. 2006 Feb;57(2):176-89. Epub 2005 Dec 12. Review.

PMID:
16344285

Supplemental Content

Support Center